Literature DB >> 24446524

Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda.

Stephen Tukwasibwe, Levi Mugenyi, George W Mbogo, Sheila Nankoberanyi, Catherine Maiteki-Sebuguzi, Moses L Joloba, Samuel L Nsobya, Sarah G Staedke, Philip J Rosenthal.   

Abstract

We explored associations between Plasmodium falciparum drug resistance-mediating polymorphisms and clinical presentations in parasitemic children enrolled in a cross-sectional survey in Tororo, Uganda, using a retrospective case-control design. All 243 febrile children (cases) and 243 randomly selected asymptomatic children (controls) were included. In a multivariate analysis adjusting for age, complexity of infection, and parasite density, the prevalence of wild-type genotypes was significantly higher in febrile children compared to asymptomatic children (pfcrt K76T: odds ratio [OR] 4.41 [95% confidence interval {CI}, 1.28-15.1]; pfmdr1 N86Y: OR 4.08 [95% CI, 2.01-8.31], and pfmdr1 D1246Y: OR 4.90 [95% CI, 1.52-15.8]), suggesting greater virulence for wild-type parasites.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24446524      PMCID: PMC4162000          DOI: 10.1093/infdis/jiu044

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.

Authors:  Frederick N Baliraine; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

2.  Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture.

Authors:  Samuel L Nsobya; Moses Kiggundu; Moses Joloba; Grant Dorsey; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 3.  PfCRT and its role in antimalarial drug resistance.

Authors:  Andrea Ecker; Adele M Lehane; Jérôme Clain; David A Fidock
Journal:  Trends Parasitol       Date:  2012-09-25

4.  Drug resistance-virulence relationship in Plasmodium falciparum causing severe malaria in an area of seasonal and unstable transmission.

Authors:  Hayder A Giha; Mustafa I Elbashir; Ishraga E A-Elbasit; Thoraya M E A-Elgadir; Gehad E ElGhazali; Margaret J Mackinnon; Hamza A Babiker
Journal:  Acta Trop       Date:  2005-12-05       Impact factor: 3.112

5.  pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum.

Authors:  Rhys Hayward; Kevin J Saliba; Kiaran Kirk
Journal:  Mol Microbiol       Date:  2005-02       Impact factor: 3.501

6.  No variation in the prevalence of point mutations in the Pfcrt and Pfmdr1 genes in isolates from Gabonese patients with uncomplicated or severe Plasmodium falciparum malaria.

Authors:  Pembe Issamou Mayengue; Yvonne Kalmbach; Saadou Issifou; Peter G Kremsner; Francine Ntoumi
Journal:  Parasitol Res       Date:  2006-10-28       Impact factor: 2.289

7.  Return of chloroquine antimalarial efficacy in Malawi.

Authors:  Miriam K Laufer; Phillip C Thesing; Nicole D Eddington; Rhoda Masonga; Fraction K Dzinjalamala; Shannon L Takala; Terrie E Taylor; Christopher V Plowe
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

8.  Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites.

Authors:  Rosalynn Ord; Neal Alexander; Sam Dunyo; Rachel Hallett; Musa Jawara; Geoffrey Targett; Christopher J Drakeley; Colin J Sutherland
Journal:  J Infect Dis       Date:  2007-10-25       Impact factor: 5.226

Review 9.  The interplay between drug resistance and fitness in malaria parasites.

Authors:  Philip J Rosenthal
Journal:  Mol Microbiol       Date:  2013-08-16       Impact factor: 3.501

10.  Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy.

Authors:  Aurore Ogouyèmi-Hounto; Nicaise Tuikue Ndam; Dorothée Kinde Gazard; Sitou d'Almeida; Lucette Koussihoude; Elvire Ollo; Carmine Azagnandji; Mourchidath Bello; Jean-Phillipe Chippaux; Achille Massougbodji
Journal:  Malar J       Date:  2013-05-01       Impact factor: 2.979

View more
  14 in total

1.  Changing Pattern of Plasmodium falciparum pfmdr1 Gene Polymorphisms in Southern Rwanda.

Authors:  Welmoed van Loon; Clara Bergmann; Felix Habarugira; Costanza Tacoli; Darius Savelsberg; Rafael Oliveira; Djibril Mbarushimana; Jules Ndoli; Augustin Sendegeya; Claude Bayingana; Frank P Mockenhaupt
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

2.  Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of Plasmodium falciparum Infection in Uganda.

Authors:  Gloria Cuu; Victor Asua; Stephen Tukwasibwe; Sam L Nsobya; Ann Nanteza; Magambo Phillip Kimuda; Arthur Mpimbaza; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

3.  Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum.

Authors:  Stanislaw J Gabryszewski; Charin Modchang; Lise Musset; Thanat Chookajorn; David A Fidock
Journal:  Mol Biol Evol       Date:  2016-02-22       Impact factor: 16.240

4.  Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.

Authors:  Christian N Nguetse; Ayola Akim Adegnika; Tsiri Agbenyega; Bernhards R Ogutu; Sanjeev Krishna; Peter G Kremsner; Thirumalaisamy P Velavan
Journal:  Malar J       Date:  2017-05-23       Impact factor: 2.979

5.  Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda.

Authors:  Stephen Tukwasibwe; Patrick Tumwebaze; Melissa Conrad; Emmanuel Arinaitwe; Moses R Kamya; Grant Dorsey; Samuel L Nsobya; Bryan Greenhouse; Philip J Rosenthal
Journal:  Malar J       Date:  2017-03-21       Impact factor: 2.979

Review 6.  Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network.

Authors:  Liwang Cui; Sungano Mharakurwa; Daouda Ndiaye; Pradipsinh K Rathod; Philip J Rosenthal
Journal:  Am J Trop Med Hyg       Date:  2015-08-10       Impact factor: 2.345

7.  Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria.

Authors:  Chimere Obiora Agomo; Wellington Aghoghovwia Oyibo; Colin Sutherland; Rachael Hallet; Mary Oguike
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

8.  Multiplicity and molecular epidemiology of Plasmodium vivax and Plasmodium falciparum infections in East Africa.

Authors:  Daibin Zhong; Eugenia Lo; Xiaoming Wang; Delenasaw Yewhalaw; Guofa Zhou; Harrysone E Atieli; Andrew Githeko; Elizabeth Hemming-Schroeder; Ming-Chieh Lee; Yaw Afrane; Guiyun Yan
Journal:  Malar J       Date:  2018-05-02       Impact factor: 2.979

9.  Molecular surveillance for drug resistance markers in Plasmodium vivax isolates from symptomatic and asymptomatic infections at the China-Myanmar border.

Authors:  Yan Zhao; Lin Wang; Myat Thu Soe; Pyae Linn Aung; Haichao Wei; Ziling Liu; Tongyu Ma; Yuanyuan Huang; Lynette J Menezes; Qinghui Wang; Myat Phone Kyaw; Myat Htut Nyunt; Liwang Cui; Yaming Cao
Journal:  Malar J       Date:  2020-08-05       Impact factor: 2.979

10.  The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data.

Authors:  Michael T Bretscher; Prabin Dahal; Jamie Griffin; Kasia Stepniewska; Quique Bassat; Elisabeth Baudin; Umberto D'Alessandro; Abdoulaye A Djimde; Grant Dorsey; Emmanuelle Espié; Bakary Fofana; Raquel González; Elizabeth Juma; Corine Karema; Estrella Lasry; Bertrand Lell; Nines Lima; Clara Menéndez; Ghyslain Mombo-Ngoma; Clarissa Moreira; Frederic Nikiema; Jean B Ouédraogo; Sarah G Staedke; Halidou Tinto; Innocent Valea; Adoke Yeka; Azra C Ghani; Philippe J Guerin; Lucy C Okell
Journal:  BMC Med       Date:  2020-02-25       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.